Published in Annu Rev Pharmacol Toxicol on January 01, 2000
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol (2008) 1.54
Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother (2009) 1.13
Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother (2002) 1.02
Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob Agents Chemother (2003) 0.94
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One (2013) 0.81
Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease. Proc Jpn Acad Ser B Phys Biol Sci (2013) 0.80
Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors. Curr Infect Dis Rep (2001) 0.80
Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2004) 0.79
Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers. Antimicrob Agents Chemother (2008) 0.78
Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2001) 0.77
Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. Sci Rep (2016) 0.75